MCLAUGHLIN MELISSA (Chief Human Resources Officer) sold 29.3% of their position (3.91K shares) of ALNYLAM PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $1.27M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−265.00
Price / share
$316.61
Trade value
$83.90K
% of position
Common Stock
Shares
−359.00
Price / share
$317.44
Trade value
$113.96K
% of position
Common Stock
Shares
−209.00
Price / share
$318.47
Trade value
$66.56K
% of position
Common Stock
Shares
−86.00
Price / share
$319.69
Trade value
$27.49K
% of position
Common Stock
Shares
−147.00
Price / share
$320.62
Trade value
$47.13K
% of position
Common Stock
Shares
−224.00
Price / share
$321.64
Trade value
$72.05K
% of position
Common Stock
Shares
−245.00
Price / share
$322.86
Trade value
$79.10K
% of position
Common Stock
Shares
−81.00
Price / share
$323.64
Trade value
$26.21K
% of position
Common Stock
Shares
−8.00
Price / share
$325.49
Trade value
$2.60K
% of position
Common Stock
Shares
−56.00
Price / share
$320.14
Trade value
$17.93K
% of position
Common Stock
Shares
−909.00
Price / share
$329.76
Trade value
$299.75K
% of position
Common Stock
Shares
−829.00
Price / share
$330.46
Trade value
$273.95K
% of position
Common Stock
Shares
−293.00
Price / share
$331.89
Trade value
$97.24K
% of position
Common Stock
Shares
−199.00
Price / share
$333.94
Trade value
$66.45K
% of position
Net shares
−3.91K
Net value
-$1.27M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/2/2026 | S · Sale | −265.00 | $316.61 | $83.90K | 2.0% | 13.35K | 13.09K |
| Common Stock Direct | 4/2/2026 | S · Sale | −359.00 | $317.44 | $113.96K | 2.7% | 13.09K | 12.73K |
| Common Stock Direct | 4/2/2026 | S · Sale | −209.00 | $318.47 | $66.56K | 1.6% | 12.73K | 12.52K |
| Common Stock Direct | 4/2/2026 | S · Sale | −86.00 | $319.69 | $27.49K | 0.7% | 12.52K | 12.43K |
| Common Stock Direct | 4/2/2026 | S · Sale | −147.00 | $320.62 | $47.13K | 1.2% | 12.43K | 12.29K |
| Common Stock Direct | 4/2/2026 | S · Sale | −224.00 | $321.64 | $72.05K | 1.8% | 12.29K | 12.06K |
| Common Stock Direct | 4/2/2026 | S · Sale | −245.00 | $322.86 | $79.10K | 2.0% | 12.06K | 11.82K |
| Common Stock Direct | 4/2/2026 | S · Sale | −81.00 | $323.64 | $26.21K | 0.7% | 11.82K | 11.74K |
| Common Stock Direct | 4/2/2026 | S · Sale | −8.00 | $325.49 | $2.60K | 0.1% | 11.74K | 11.73K |
| Common Stock Direct | 4/6/2026 | S · Sale | −56.00 | $320.14 | $17.93K | 0.5% | 11.73K | 11.67K |
| Common Stock Direct | 4/6/2026 | S · Sale | −909.00 | $329.76 | $299.75K | 7.8% | 11.67K | 10.76K |
| Common Stock Direct | 4/6/2026 | S · Sale | −829.00 | $330.46 | $273.95K | 7.7% | 10.76K | 9.94K |
| Common Stock Direct | 4/6/2026 | S · Sale | −293.00 | $331.89 | $97.24K | 2.9% | 9.94K | 9.64K |
| Common Stock Direct | 4/6/2026 | S · Sale | −199.00 | $333.94 | $66.45K | 2.1% | 9.64K | 9.44K |
| Total | −3.91K | -$1.27M | ||||||